Global cervical cancer vaccine market research report

1. India Adhesives Market Forecast & Opportunities, 2020 Opportunities, 2020 Global Cervical Cancer Vaccine Market P h a r m a & H e a l t h c a r e C o n s u l t a n t s

2. Re s e a rc h M e t h o d o l o g y Baseline Methodology : For the study, Pharmaion has gathered information through primary research with respondents in cervical cancer vaccine manufacturers across the globe. We also gathered insights through an exhaustive search of credible paid databases and our internal database. Since an HPV(Human Papilloma Vaccine) is used by both males and female, the report has captured only female population using the vaccine for prevention against cervical cancer. Our team of analysts has then prudently evaluated all the collected information and presented the same in chronological order to depict a meaningful and clear picture of cervical cancer vaccine market in all the regions across the world. While compiling the data, we have also validated all the collected information from multiple sources and data warehouses, in order to present accurate and precise information of the concerned industry. The information has then been verified with primary research surveys with competitors to arrive at logical figures. Companies Interviewed Merck Co & Inc., Sanofi Pasteur MSD, GlaxoSmithKline Sources : World Health Organisation, GLOBOLCAN, Company Annual Reports and Investors Presentations 2 © Pharmaion

3. Ta b l e o f C o n te n t s S No. Contents 1. Product Overview 2. Research Methodology 3. Analyst View Global Cervical Cancer Patient Epidemiology 4. Global Cervical Cancer Vaccine Market Outlook 5. 5.1. Market Size & Forecast 5.1.1. By Value 5.2. Market Share & Forecast 5.2.1. By Region 5.2.2. By Company United States Cervical Cancer Vaccine Market Outlook 6. 6.1. Market Size & Forecast 6.1.1. By Value 6.1.2. By Volume 6.2. Market Share & Forecast 6.2.1. By Company 6.3. US Cervical Cancer Patient Epidemiology Europe Cervical Cancer Vaccine Market Outlook 7. 7.1. Market Size & Forecast 7.1.1. By Value 7.1.2. By Volume 2 7.2. Market Share & Forecast 7.2.1. By Company © Pharmaion

4. Ta b l e o f C o n te n t s S No. Contents 7.3. Europe Cervical Cancer Patient Epidemiology 8. ROW Cervical Cancer Vaccine Market Outlook 8.1. Market Size & Forecast 8.1.1. By Value 8.2. Market Share & Forecast 8.2.1. By Company 9. Market Dynamics 9.1. Drivers 9.2. Challenges Market Trends & Developments 10.1. New Product Development 10.2. Patient Assistance Program 10.3. Reduced HPV Vaccine Dosage 10.4. Expanding Involvement of Pharmacists Competitive Landscape 11.1. Merck & Co., Inc. (NYSE: MRK) 11.1.1. Company Overview 11.1.2. Regulatory Footprint: Gardasil 11.1.3. Clinical Highlights: Gardasil 11.2. GlaxoSmithKline plc (LSE:GSK.L) 11.2.1. Company Overview 11.2.2. Regulatory Footprint: Cervarix 11.2.3. Clinical Highlights: Cervarix 11.3. Xiamen Innovax Biotech Co., Ltd. 10. 11. 3 © Pharmaion

5. Ta b l e o f C o n te n t s S No. Contents 12. Strategic Recommendations 13. About Us & Disclaimer 4 © Pharmaion

6. I n d u s t r y B r i e f Global Cervical Cancer Vaccine Market to Cross US$ 1.6 billion by 2020 Growing prevalence of cervical cancer coupled with favorable government initiatives to drive global cervical cancer vaccine market through 2020 According Opportunities, 2020”, global cervical cancer vaccine market is anticipated to cross US$ 1.6 billion by 2020. Growth in the market is anticipated on account of rising prevalence of cervical cancer, various promising late- stage pipeline candidates and vendors' patient-assistance programs. Moreover, governments in various countries are also organizing different programs and initiatives to increase awareness regarding cervical cancer and associated vaccines available in the market. Furthermore, reduction in the number of recommended number of doses of HPV immunisation from three to two is also expected to have a positive impact on the global cervical cancer vaccine market during 2015 - 2020. to recently published Pharmaion report, “Global Cervical Cancer Vaccine Market Cervical cancer vaccines are biological preparations that stimulate or strengthen a person's immune system against cancer. Majorly, two cervical cancer vaccines, namely, Gardasil (Merck & Co., Inc.) and Cervarix (GlaxoSmithKline plc), are available across the globe. Gardasil and Cervarix provide protection against four and two types of HPV strains, respectively. As of 2014, Merck & Co., Inc. and GlaxoSmithKline plc were the only two HPV vaccine producers in the global cervical cancer market. However, Xiamen Innovax Biotech Co., Ltd. plans to enter the global cervical cancer market with the launch of its bivalent HPV vaccine Cecolin. Region-wise, the United States dominated the global cervical cancer market and is anticipated to continue its dominance through 2020 on account of the launch of its nine-valent HPV vaccine, Gardasil 9, in 2014, which protects against the infection of all nine types of HPV. Moreover, growing prevalence of cervical cancer, high per capital income levels and favorable reimbursement policies are expected to result in continuance of US as the largest global cervical cancer vaccine market through 2020. “Various strategic alliances are being signed between public and private entities for increasing the penetration of cervical cancer vaccine. For instance, GAVI Alliance aims to immunize about 2 million females in developing regions in 2015 using the HPV vaccines Cervarix and Gardasil, which are being supplied at a low cost by GlaxoSmithKline and Merck. Moreover, in the US, National Vaccine Program Office (NVPO) inked a partnership contract with the American Pharmacists Association (APhA) in 2015 in order to utilize alternative vaccination sites, such as pharmacies, to increase the vaccination access and coverage rates in the country.” said Mr. Karan Chechi, Research Director with Pharmaion, a research based global pharmaceutical and healthcare consulting firm. 6 © Pharmaion

7. P ro d u c t O ve r v i e w Cervical Cancer occurs when abnormal cells on the surface of cervix, which is the lower part of the uterus of a woman’s body, begin to divide rapidly. The cancer is mainly caused by the infection of Human Papilloma Virus (HPV), which is transmitted through sexual contact with an HPV-infected person. Typically, there are two strains of Human Papilloma Virus (HPV) which causes cervical cancer:  HPV X  HPV X Cervical Cancer Vaccine: The vaccines which are used to prevent the infection caused by different HPV types, associated with the development of cervical cancer, are termed as cervical cancer vaccine. 7 © Pharmaion

8. P ro d u c t O ve r v i e w Process of Development of Cervical Cancer after an HPV Infection HPV Virus Persistence + Progression Cervix Infected with high-risk HPV Precancerous Lesion Normal Cervix Cancer Invasion Regression Clearance Persistence of a HPV virus infection for more than a year increases the risk of cervical cancer. Due to the HPV infection, cervix witnesses abnormal cellular changes known as Cervical Intraepithelial Neoplasia (CIN). Majority of CIN rapidly regresses, however, they posses the potential to develop into invasive cervical cancer. It takes approximately X or X years for the development of cervical cancer from the time of high-risk HPV infection. 8 © Pharmaion

9. S a m p l e D a t a - S n a p s h o t Australia HPV 3 Dose Vaccine Coverage for United States Gardasil and Cervarix Vaccine for Children, NSW- XXXX Females of Age 15 years, By State, By Average Selling Price (ASP), 2010-2014, (USD/Dose) VIC- XXXX 11 Number, 2014 9 WA- XXXX 7 SA- XXXX 5 5 7 4 3 3 TAS- XXXX 2 1 6 ACT- XXXX 5 2010 2011 2012 2013 2014 NT- XXXX 4 Gardasil 3 United States Percentage of 13 to 17 Year-old Girls Completing HPV Vaccine 3 Dose, 2012 2 X % 1 X% X% X% X% X% X% X% NSW VIC WA SA TAS ACT NT X% X% X % X % X% X % X% X% X% X % X% X% X% X% X% X% United States Cervical Cancer Vaccine Market X% X% X% X% X%X Share, By Company, By Value, 2010-2020F >= X% X% X % % X% X% X% X% 50.00% 50.10% 50.20% 50.30% 50.40% 50.50% 50.60% 50.70% 50.80% 50.90% 51.00% X% X% Alaska X% X% 4.00% 4.01% 4.02% 4.03% 4.04% 4.05% 4.06% 4.07% 4.08% 4.09% 4.10% Hawaii <= X% 2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F GlaxoSmithKline Global Cervical Cancer Vaccine Market Share, By Region, By Value, 2010-2020F 36.06% 36.07% 36.08% 36.03%36.04% 36.00% 36.01% 36.02% 36.09% 36.10% 36.05% Global Cervical Cancer Vaccine Market Size, By 31.08% 31.09% 31.10% 31.06% 31.07% 31.04% 31.05% 31.02% 31.03% 31.00% 31.01% Value, 2010-2020F (USD Million) 28.10% 28.06% 28.07% 28.08% 28.09% 28.01% 28.02% 28.03% 28.04% 28.05% 28.00% 12 11 10 9 8 7 5 4 3 2 2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F 1 9 2010 2011 2012 2013 2014 2015E 2016F 2017F 2018F 2019F 2020F Rest of the World European Union United States © Pharmaion

10. Re p o r t O rd e r i n g Report Name: Global Cervical Cancer Vaccine Market Opportunities, 2020 Report Price License Type Price Single User License $4000 Single User License Print $4500 Enterprise License $8000 To View Sample OR Purchase Report 10 © Pharmaion ©

11. A b o u t U s & D i s c l a i m e r About Us : Pharmaion is a research based management consulting firm focused exclusively on Healthcare & Pharmaceutical industry. Pharmaion’s core values are value, integrity and insight. Led by a team of dynamic industry experts, Pharmaion provides its customers with high value market research and advisory services that helps them identify new market opportunities, growth engines and innovative ways to capture the market share. As a result, Pharmaion’s clients lead rather than follow market trends. Not bound by legacy, Pharmaion’s cutting-edge research model leverages its decades of research knowledge and an increased use of technology as engines of innovation to deliver unique research value. Provided as an alternative to traditional market research, Pharmaion’s reports do not just deliver data and knowledge rather highlights the insights in a more usable and interactive format for its clients. Pharmaion is committed to assisting customers worldwide with their unique market research needs by providing them with comprehensive, value-added solutions and professional market intelligence services. Pharmaion employs the industry’s best-trained industry Analysts and Consultants, which advises and assists customers in meeting their full service market research and consulting requirements. Related Reports India Stem Cell Market Forecast & Opportunities, 2020 Global Tissue Engineered Medical Devices Market Forecast & Opportunities, 2020 Global Cervical Cancer Vaccine Market Forecast & Opportunities, 2020 Disclaimer : The contents of this report are based on information generally available to the public from sources believed to be reliable. No representation is made that it is timely, accurate or complete. Pharmaion Consultants has taken due care and caution in compilation of data as this has been obtained from various sources including which it considers reliable and first hand. However, Pharmaion Consultants does not guarantee the accuracy, adequacy or completeness of any information and it is not responsible for any errors or omissions or for the results obtained from the use of such information and especially states that it has no financial liability whatsoever to the subscribers / users of this report. The information herein, together with all estimates and forecasts, can change without notice. All the figures provided in this document are indicative of relative market size and are strictly for client’s internal consumption. Usage of the same for purpose other than internal will require prior approval of Pharmaion Consultants. NORTH AMERICA Pharmaion Consultants LLC 708 3RD Avenue, 6th Floor, New York, NY, United State, 10017 sales@pharmaion.com +1 646 360 1656 www.pharmaion.com ASIA PACIFIC Pharmaion Consultants Pvt. Ltd. A – 51, Sector 57, Noida, National Capital Region, India - 201301 sales@pharmaion.com +91 - 120 - 452 3900 www.pharmaion.com 105 © Pharmaion